Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 11:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 618 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: buprenorphine hydrochloride Clear all
Completed No phase listed Observational Accepts healthy volunteers

Innovatively Increasing PCP Prescribing of Buprenorphine: Measurement Based Care and Integrated Electronic Solution

NCT04059016
View directory record Official record
Conditions
Opioid Abuse and Addiction
Interventions
MBC4OUD
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 3 Interventional Results available

Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study

NCT01151098
View directory record Official record
Conditions
Chronic Nonmalignant Pain
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
19
States / cities
Phoenix, Arizona • Trumbull, Connecticut • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Providing Suboxone and PrEP Using Telemedicine

NCT04521920
View directory record Official record
Conditions
Opioid Use, Opioid-use Disorder, Risk Reduction, Hiv
Interventions
Suboxone, PrEP
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Charlotte, North Carolina • Durham, North Carolina • Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole

NCT01259115
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine transdermal patch, Ketoconazole tablet, Placebo to match ketoconazole tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 54 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 2Phase 3 Interventional

Opioid Use Disorder Treatment Linkage at Strategic Touchpoints Using Buprenorphine

NCT04991974
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Patient Navigation, Buprenorphine
Behavioral · Drug
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 25, 2026, 11:05 PM EDT
Withdrawn Phase 4 Interventional

Psychopharmacological Treatment of Emotional Distress

NCT06133114
View directory record Official record
Conditions
Suicide Crisis Syndrome, Psychological Distress
Interventions
Clonazepam, Olanzapine, Buprenorphine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 25, 2026, 11:05 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers

NCT04251819
View directory record Official record
Conditions
Acute Pain, Analgesia
Interventions
Placebos, Baclofen 5 mg, Baclofen 10mg
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increasing MAT Engagement With Financial Incentives

NCT04585399
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Contingency management
Behavioral
Lead sponsor
Rowan University
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 3 Interventional Results available

Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL

NCT02696434
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Naltrexone, Placebo, Buprenorphine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Lauderhill, Florida • Oakland Park, Florida • Winfield, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 25, 2026, 11:05 PM EDT
Terminated Phase 1 Interventional

Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).

NCT06406400
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
AZD4041, Itraconazole, Buprenorphine, Buprenorphine / Naloxone, Hydromorphone, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Not applicable Interventional

Repeated-dose Brief Intervention to Reduce Overdose and Risk Behaviors Among Naloxone Recipients

NCT02093559
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Overdose
Interventions
Brief counseling Intervention
Behavioral
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Early Phase 1 Interventional Results available

Safety and Tolerability of Cannabidiol Among Persons With Opioid Use Disorder Receiving Methadone or Buprenorphine

NCT05076370
View directory record Official record
Conditions
Addiction
Interventions
CBD Day 1, CBD Day 2, CBD Day 3
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 2 Interventional

Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2

NCT00000299
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 1 Interventional

Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults

NCT01046539
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
RDC-0313 + Buprenorphine, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Not applicable Interventional

Mindful Body Awareness With Medication Treatment for Opioid Use Disorder

NCT04082637
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Mindful Awareness in Body-oriented Therapy
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Bellingham, Washington • Port Angeles, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Sep 25, 2026, 11:05 PM EDT
Completed No phase listed Observational Results available

Evaluation of Long-term Buprenorphine Plasma Exposure

NCT03752528
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Blood sample collection, Urine sample collection
Diagnostic Test
Lead sponsor
Indivior Inc.
Industry
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
11
States / cities
Hamilton, Alabama • Tampa, Florida • Prairie Village, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Sep 25, 2026, 11:05 PM EDT
Withdrawn Phase 2 Interventional

Olanzapine in OUD Patients

NCT05179772
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Olanzapine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 3 Interventional Results available

Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children

NCT01324570
View directory record Official record
Conditions
Pain
Interventions
Buprenorphine transdermal system
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
7 Years to 16 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
22
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 2 Interventional

Alternate Day Buprenorphine Administration, Phase X - 15

NCT00000233
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
34 Years to 51 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 16, 2005 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder

NCT04976855
View directory record Official record
Conditions
Healthy Volunteer, Opioid-use Disorder
Interventions
INDV-2000, Placebo, SUBOXONE® sublingual film
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • DeSoto, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Abuse Liability of Suboxone Versus Subutex

NCT00710385
View directory record Official record
Conditions
Opioid-related Disorders
Interventions
Heroin, Naloxone, Low Bup Dose, High Bup Dose, Low Bup/Nal Dose, High Bup/Nal Dose, Placebo (PCB)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 25, 2026, 11:05 PM EDT
Not listed Phase 4 Interventional

Buprenorphine for Cancer Pain

NCT05910190
View directory record Official record
Conditions
Cancer-Related Pain
Interventions
Use of buprenorphine with FAO > 30 OME, CPM Rx application use
Drug · Behavioral
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2023 · Synced Sep 25, 2026, 11:05 PM EDT
Terminated Phase 4 Interventional Results available

Buprenorphine as a Treatment in Opiate Dependent Pain Patients

NCT00552578
View directory record Official record
Conditions
Opiate Addiction, Refractory Pain
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2011 · Synced Sep 25, 2026, 11:05 PM EDT
Completed Not applicable Interventional

Behavioral Activation for Opioid Use Disorder

NCT05262725
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Values-based Behavioral Activation
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Sep 25, 2026, 11:05 PM EDT